RxDoctor Payments Data

Douglas Council

Psychiatric/Mental Health · Marion, LANPI 1144250606

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.6% of the total across 242 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,299in general payments, 2019–2025

Across 242 payments — averaging $30.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$840
  • Neurocrine Biosciences, Inc.$799
  • Teva Pharmaceuticals USA, Inc.$714
  • Johnson & Johnson$604
  • Corium, LLC$546
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$7,05197%
  • Education$2483%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,299 in reported general payments places this provider in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole40$62,275
VraylarCariprazine Hcl24$33,760
Atomoxetine Hcl12$857
Trazodone Hcl64$840
Aripiprazole16$658
Buspirone Hcl89$650
Oxcarbazepine24$633
Bupropion XlBupropion Hcl48$612
Fluvoxamine Maleate19$608
Mirtazapine30$514
Duloxetine Hcl50$314
Fluoxetine Hcl29$312
Olanzapine18$261
Escitalopram Oxalate39$238
Clonazepam42$199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$456$62,27540 claims
AbbVieVraylar$1,528$33,76024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Marion

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →